EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSEEUG00000011744
Gene Symbol: GABRB3
1 External references
256 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSEEUG00000010781
Gene Symbol: GABRD
1 External references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSEEUG00000009152
Gene Symbol: GABRG1
1 External references
189 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSEEUG00000011874
Gene Symbol: GABRG3
1 External references
257 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Theta

Ensembl ID : ENSEEUG00000007557
Gene Symbol: GABRQ
1 External references
86 Possible Orthologues:

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSEEUG00000008006
Gene Symbol: GLP1R
1 External references
133 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSEEUG00000014254
Gene Symbol: GLP2R
1 External references
205 Possible Orthologues:

Glucokinase

Ensembl ID : ENSEEUG00000001219
Gene Symbol: GCK
1 External references
216 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSEEUG00000002474
Gene Symbol: GBA1
1 External references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSEEUG00000002969
Gene Symbol: GRIA1
1 External references
325 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSEEUG00000006360
Gene Symbol: GRIA2
1 External references
322 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSEEUG00000006366
Gene Symbol: GRIA3
1 External references
249 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).